Black Rock Inc. Atreca, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.13 - $0.38 $71,198 - $208,119	-547,684 Reduced 46.19%	637,974 $82,000
Q3 2023 Nov 13, 2023	SELL	$0.26 - $1.12 $1,593 - $6,862	-6,127 Reduced 0.51%	1,185,658 $308,000
Q2 2023 Aug 11, 2023	SELL	$0.88 - $1.22 $135,395 - $187,706	-153,858 Reduced 11.43%	1,191,785 $1.17 Million
Q1 2023 May 12, 2023	SELL	$0.91 - $1.82 $76,333 - $152,667	-83,883 Reduced 5.87%	1,345,643 $1.53 Million
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $210,686 - $453,786	-270,111 Reduced 15.89%	1,429,526 $1.14 Million
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $10,805 - $18,621	-6,796 Reduced 0.4%	1,699,637 $2.67 Million
Q2 2022 Aug 12, 2022	SELL	$1.56 - $3.25 $1.96 Million - $4.09 Million	-1,257,410 Reduced 42.42%	1,706,433 $3.05 Million
Q1 2022 May 12, 2022	BUY	$1.61 - $5.2 $20,215 - $65,291	12,556 Added 0.43%	2,963,843 $9.4 Million
Q4 2021 Feb 10, 2022	SELL	$2.87 - $6.29 $26,315 - $57,673	-9,169 Reduced 0.31%	2,951,287 $8.94 Million
Q3 2021 Nov 09, 2021	BUY	$4.91 - $9.07 $416,888 - $770,097	84,906 Added 2.95%	2,960,456 $18.4 Million
Q2 2021 Aug 11, 2021	BUY	$7.82 - $13.8 $22.5 Million - $39.7 Million	2,875,550 New	2,875,550 $24.5 Million

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.